A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
224estimated
Sites
15
Country
Russia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-07 | actual | When the study began enrolling |
| Primary completion | 2026-07-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Kidney Disease With High Proteinuria
Interventions
- Drug: Zibotentan/Dapagliflozin
- Drug: Dapagliflozin
Primary outcome
what the primary-completion date above is the date OFChange in log-transformed Urinary Albumin to Creatinine Ratio (UACR) from baseline
measured At Week 12
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed